Organogenesis Q4 revenue $128.6M (+20% YoY), FY22 guidance $485M-$515M

Organogenesis Holdings Inc.

2021-FY EPS reported $0.71 revenue$468,059,000

Q4 net revenue $128.6M (up 20% YoY); Advanced Wound Care $121.4M (+30%), Surgical & Sports Medicine $7.2M (-45%).
Q4 GAAP net income $51.7M ($0.39 diluted EPS) vs $18.3M ($0.15) a year ago; adjusted EBITDA $26.3M.
FY2021 net revenue $468.1M (+38% YoY); net income $94.9M ($0.71 diluted EPS); adjusted EBITDA $89.1M.
FY2022 guidance: net revenue $485M-$515M (+4% to +10% YoY); net income $56.5M-$71.5M; adjusted EBITDA $79.9M-$95.3M.
Cash and equivalents $114.5M; total debt $73.6M as of Dec 31, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.